Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed (09/09/2021)

12.09.2021

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced that positive clinical data on the antiviral efficacy of Carragelose-containing lozenges have been published in the peer-reviewed journal International Journal of General Medicine. The clinical study investigated whether sucking of one Carragelose-containing (10 mg) lozenge would lead to sufficient iota-carrageenan concentrations in the saliva of 31 healthy subjects to neutralize seven human respiratory viruses that cause common colds as well as COVID-19. “These results further confirm what we have seen in several recent studies, both conducted by us and independently: Carragelose is an effective tool against respiratory viruses, including SARS-CoV-2. We are glad that with the data published here we were able to confirm that Carragelose lozenges release multiple times more active compound than necessary to neutralize all tested viruses,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. “It has become increasingly clear that the current pandemic will not end abruptly, but rather is SARS-CoV-2 here to stay. In light of the emerging variants of concern it will be important to have multiple lines of defence against COVID-19. Carragelose has the potential to act as an additional measure alongside vaccines to help contain the pandemic and to protect people.”

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (09/09/2021)


Partners









latest 21st Austria

21st Austria weekly - Marinomed (09/09/2021)


12.09.2021


Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced that positive clinical data on the antiviral efficacy of Carragelose-containing lozenges have been published in the peer-reviewed journal International Journal of General Medicine. The clinical study investigated whether sucking of one Carragelose-containing (10 mg) lozenge would lead to sufficient iota-carrageenan concentrations in the saliva of 31 healthy subjects to neutralize seven human respiratory viruses that cause common colds as well as COVID-19. “These results further confirm what we have seen in several recent studies, both conducted by us and independently: Carragelose is an effective tool against respiratory viruses, including SARS-CoV-2. We are glad that with the data published here we were able to confirm that Carragelose lozenges release multiple times more active compound than necessary to neutralize all tested viruses,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. “It has become increasingly clear that the current pandemic will not end abruptly, but rather is SARS-CoV-2 here to stay. In light of the emerging variants of concern it will be important to have multiple lines of defence against COVID-19. Carragelose has the potential to act as an additional measure alongside vaccines to help contain the pandemic and to protect people.”

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (09/09/2021)




 

Bildnachweis

Aktien auf dem Radar:Bawag, AT&S, Wienerberger, Frequentis, Marinomed Biotech, SBO, Verbund, ATX TR, Rosgix, Erste Group, CA Immo, Andritz, Agrana, Flughafen Wien, Immofinanz, Uniqa, S Immo, RBI, OMV, ATX, ATX Prime, Addiko Bank, AMS, BTV AG, Cleen Energy, Kapsch TrafficCom.


Random Partner

Strabag
Strabag SE ist ein europäischer Technologiekonzern für Baudienstleistungen. Das Angebot umfasst sämtliche Bereiche der Bauindustrie und deckt die gesamte Bauwertschöpfungskette ab. Durch das Engagement der knapp 72.000 MitarbeiterInnen erwirtschaftet das Unternehmen jährlich eine Leistung von rund 14 Mrd. Euro (Stand 06/17).

>> Besuchen Sie 65 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten